BCDA
NASDAQBioCardia Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News · 26 weeks69-36%
2026-03-012026-08-23
Mix3890d
- Insider22(58%)
- SEC Filings9(24%)
- Other5(13%)
- Earnings2(5%)
Latest news
25 items- SECBioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - BioCardia, Inc. (0000925741) (Filer)
- PRBioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for ApprovalSUNNYVALE, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces receipt of FDA confirmation of the outcome of its Pre-Submission Meeting on the Helix Transendocardial Delivery Catheter System (Helix). FDA has reviewed and accepted the meeting minutes provided by BioCardia in May 2026 which are now considered final. This ratifies the understanding with FDA that BioCardia shared in its May 8, 2026 press release and 8-K filing. "We intend to submit the follow-on pre-submission for Helix incorporating agency advice this quarter which cou
- SECBioCardia Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - BioCardia, Inc. (0000925741) (Filer)
- INSIDERPresident and CEO Altman Peter bought $5,022 worth of shares (5,400 units at $0.93), increasing direct ownership by 1% to 381,115 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERPresident and CEO Altman Peter bought $1,748 worth of shares (1,900 units at $0.92), increasing direct ownership by 0.51% to 375,785 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- SECBioCardia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BioCardia, Inc. (0000925741) (Filer)
- SECSEC Form 10-Q filed by BioCardia Inc.10-Q - BioCardia, Inc. (0000925741) (Filer)
- PRBioCardia Reports Second Quarter 2026 Business Highlights and Financial ResultsSUNNYVALE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter 2026 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2026 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management’s formal remarks, there will be a question-and-answer session. "This second quarter, BioCardia had three important positive meetings with regulatory agencies in Jap
- PRBioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026SUNNYVALE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the second quarter of 2026 by conference call on Wednesday, August 12, 2026 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to: https://dpregister.com/sreg/10211154/104a4f51d2e. Please note that registered participants will receive their dial-in number upon registration. For those who have not reg
- INSIDERPresident and CEO Altman Peter bought $3,900 worth of shares (5,000 units at $0.78), increasing direct ownership by 1% to 373,885 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERPresident and CEO Altman Peter bought $415 worth of shares (500 units at $0.83), increasing direct ownership by 0.14% to 368,885 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERPresident and CEO Altman Peter bought $3,754 worth of shares (4,300 units at $0.87), increasing direct ownership by 1% to 368,385 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERPresident and CEO Altman Peter bought $7,175 worth of shares (7,500 units at $0.96), increasing direct ownership by 2% to 369,485 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERPresident and CEO Altman Peter bought $5,208 worth of shares (5,400 units at $0.96), increasing direct ownership by 2% to 361,985 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERSEC Form 4 filed by Director Stertzer Simon H4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERSEC Form 4 filed by Director Slosman Marvin4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERPresident and CEO Altman Peter covered exercise/tax liability with 54,606 shares, decreasing direct ownership by 13% to 356,585 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERChief Financial Officer Mcclung David covered exercise/tax liability with 23,125 shares, decreasing direct ownership by 17% to 114,245 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERSenior Vice President, Devices Gillis Edward M covered exercise/tax liability with 17,269 shares, decreasing direct ownership by 24% to 54,126 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERSEC Form 4 filed by Director Blank Andrew Scott4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERSEC Form 4 filed by Director Allen Jim L.4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERSEC Form 4 filed by Director Moyes Jay M4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERSEC Form 4 filed by Director Facteau Bill4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERPresident and CEO Altman Peter was granted 110,625 shares, increasing direct ownership by 37% to 411,191 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERChief Financial Officer Mcclung David was granted 60,483 shares, increasing direct ownership by 79% to 137,370 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
BCDA FAQ
6 questionsWhat does BioCardia Inc. do?
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery...Where does BCDA stock trade?
BioCardia Inc. (BCDA) is listed on NASDAQ.What sector and industry is BCDA in?
BioCardia Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about BCDA?
BioCardia Inc. has had 1 recent analyst action on file. The most recent action was from HC Wainwright & Co.: Buy with a $900.00 price target on 2021-12-20. Recent price targets cluster around $900.00.What companies are similar to BCDA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare BCDA side-by-side with any of them on Quantisnow.How can I track BCDA on Quantisnow?
Quantisnow aggregates BioCardia Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BCDA to receive live email and push alerts on every new disclosure.